DOSAGE INDEX / BLEND
Cagrilintide + Semaglutide
Research, reported schedules and supply planning.
Review CagriSema weight-loss and diabetes trials, component comparisons, the missed REDEFINE 4 target, safety findings and current research status.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 0.25–2.4 mg of each component per week
- Frequency
- Once weekly
- Cycle / observation period
- At least 16 weeks in the source
- Route / research model
- Subcutaneous
A commercial 1:1 research blend must not be assumed equivalent to a clinical-trial combination formulation.
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Acidic diluent / GA water: under formulation review. Acetic-acid concentration, glycerin content, peptide salt form and intended laboratory use must be specified before compatibility can be assessed. No acidic diluent has been assigned to this product or blend.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 10 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
Studies of individual ingredients do not establish the effects of this finished combination. Combination studies are identified explicitly below.
- A phase 1b trial studied multiple cagrilintide dose groups added to semaglutide. Its control groups received placebo with semaglutide, so the comparison was about adding cagrilintide to that background treatment. Safety, tolerability, drug exposure and weight-related measurements were assessed. [1]
- REDEFINE 2 randomized 1,206 participants with type 2 diabetes to the combination or placebo for 68 weeks. Mean weight change was -13.7% versus -3.4% in the treatment-policy analysis. Gastrointestinal adverse events were reported in 72.5% versus 34.4%. [2]
- In its February 2026 announcement, Novo Nordisk reported that the 809-person, open-label REDEFINE 4 trial did not meet its primary noninferiority target against tirzepatide at 84 weeks. Sponsor-reported efficacy estimates were 23.0% weight loss with CagriSema versus 25.5% with tirzepatide; treatment-regimen estimates were 20.2% versus 23.6%. [3]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 13 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- Original phase 1b report
- Original REDEFINE 2 publication
- Sponsor announcement
- Bachem: peptide solubility and handling guidance (laboratory methods)
- Lancet Diabetes Endocrinology (2024)Further reading · Listed in reference bibliography.
- Lancet (2021)Further reading · Listed in reference bibliography.
- Lancet (2021)Further reading · Listed in reference bibliography.
- StatPearls (2025)Further reading · Listed in reference bibliography.
- Cureus (2024)Further reading · Listed in reference bibliography.
- WHO (2010)Further reading · Listed in reference bibliography.
- U.S. Food and Drug AdministrationRegulatory / product information · Listed in reference bibliography.
- LibreTexts (2020)Further reading · Listed in reference bibliography.
- CDC (2024)General guidance · Listed in reference bibliography.
- ScienceDirect (2024)Further reading · Listed in reference bibliography.
- PMC (2019)Further reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.